The clinical study has been launched.
Today in Ostrava, the clinical evaluation of a medical device was officially launched as part of a clinical study aimed at demonstrating the safety of non-invasive inhalation of molecular hydrogen in patients with mild cognitive impairment (MCI), a condition that may precede the development of Alzheimer’s dementia.
The study connects a Czech clinical center with a leading Japanese scientific team and represents an important step toward moving molecular hydrogen from the field of research into regular use in healthcare. The project is led by the Czech company H2 Medical Technologies, part of the H2 Global Group.